U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Alirocumab

Last Revision: November 15, 2023.

Estimated reading time: 1 minute

CASRN: 1245916-14-6

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of alirocumab during breastfeeding. Because alirocumab is a large protein molecule with a molecular weight of 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Until more data become available, alirocumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]
2.
Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
3.
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66. [PubMed: 36931808]

Substance Identification

Substance Name

Alirocumab

CAS Registry Number

1245916-14-6

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Anticholesteremic Agents

Antilipemic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500752PMID: 29999811

Views

Related information

Similar articles in PubMed

  • Review Evolocumab.[Drugs and Lactation Database (...]
    Review Evolocumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Dupilumab.[Drugs and Lactation Database (...]
    Review Dupilumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Sarilumab.[Drugs and Lactation Database (...]
    Review Sarilumab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Basiliximab.[Drugs and Lactation Database (...]
    Review Basiliximab.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Tildrakizumab.[Drugs and Lactation Database (...]
    Review Tildrakizumab.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...